DNA Analysis and Malignant Hyperthermia Susceptibility

Ording H. , Brancadoro V. , Cozzolino S. , Ellis F.R. , Glauber V. , Gonano E.F. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group. Acta Anaesthesiol Scand 1997; 41: 955–966.

McCarthy T.V. , Quane K.A. , Lynch P.J. Ryanodine receptor mutations in malignant hyperthermia and central core disease. Hum Mutat 2000; 15: 410–417.

MacLennan D.H. , Duff C. , Zorzato F. , Fujii J. , Phillips M. , Korneluk R.G. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature 1990; 343: 559–561.

McCarthy T.V. , Healy J.M. , Heffron J.J. , Lehane M. , Deufel T. , Lehmann-Horn F. Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature; 1990; 343: 562–564.

Stowell K.M. , Brown R. , James D. , Couchman K. , Hodges M. , Pollock N. Malignant Hyperthermia in New Zealand. NZ Bioscience 1999; 7: 12–17.

MacLennan D.H. , Otsu K. , Fujii J. , Zorzato F. , Phillips M.S. , O'Brien P.J. The role of the skeletal muscle ryanodine receptor gene in malignant hyperthermia. Symp Soc Exp Biol 1992; 46: 189–201.

Robinson R. , Carpenter D. , Shaw M.A. , Halsall J. , Hopkins P. Mutations in RY R1 in malignant hyperthermia and central core disease. Hum Mutat 2006; 27: 977–989.

Urwyler A. , Deufel T. , McCarthy T. , West S. Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. Br J Anaesth 2001; 86: 283–287.

Brandt A. , Schleithoff L. , Jurkat-Rott K. , Klingler W. , Baur C. , Lehmann-Horn F. Screening of the ryanodine receptor gene in 105 malignant hyperthermia families: novel mutations and concordance with the in vitro contracture test. Hum Mol Genet 1999; 8: 2055–2062.

Monnier N. , Krivosic-Horber R. , Payen J.F. , Kozak-Ribbens G. , Nivoche Y. , Adnet P. Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility. Anesthesiology 2002; 97: 1067–1074.

Rueffert H. , Olthoff D. , Deutrich C. , Thamm B. , Froster U.G. Homozygous and heterozygous Arg614Cys mutations (1840C->T) in the ryanodine receptor gene co-segregate with malignant hyperthermia susceptibility in a German family. Br J Anaesth 2001; 87: 240–245.

Anderson A.A. , Brown R.L. , Polster B. , Pollock N. , Stowell K.M. Identification and biochemical characterization of a novel ryanodine receptor gene mutation associated with malignant hyperthermia. Anesthesiology 2008; 108: 208–215.

European Malignant Hyperthermia Group. From: http://www.emhg.org Accessed February 2008.

Querfurth H.W. , Haughey N.J. , Greenway S.C. , Yacono P.W. , Golan D.E. , Geiger J.D. Expression of ryanodine receptors in human embryonic kidney (HEK293) cells. Biochem J 1998; 334: 79–86.

Richter M. , Schleithoff L. , Deufel T. , Lehmann-Horn F. , Herrmann-Frank A. Functional characterization of a distinct ryanodine receptor mutation in human malignant hyperthermia-susceptible muscle. J Biol Chem 1997; 272: 5256–5260.

Yang T. , Ta T.A. , Pessah I.N. , Allen P.D. Functional defects in six ryanodine receptor isoform-1 (RyR1) mutations associated with malignant hyperthermia and their impact on skeletal excitation-contraction coupling. J Biol Chem 2003; 278: 25722–25730.

McKinney L.C. , Butler T. , Mullen S.P. , Klein M.G. Characterization of ryanodine receptor-mediated calcium release in human B cells: relevance to diagnostic testing for malignant hyperthermia. Anesthesiology 2006; 104: 1191–1201.

Sei Y. , Brandom B.W. , Bina S. , Hosoi E. , Gallagher K.L. , Wyre H.W. Patients with malignant hyperthermia demonstrate an altered calcium control mechanism in B lymphocytes. Anesthesiology 2002; 97: 1052–1058.

Sei Y. , Gallagher K.L. , Daly J.W. Multiple effects of caffeine on Ca²⁺ release and influx in human B lymphocytes. Cell Calcium 2001; 29: 149–160.

Lopez J.R. , Linares N. , Pessah I.N. , Allen P.D. Enhanced response to caffeine and 4-CmC in malignant hyperthermia susceptible muscle is related in part to chronically elevated resting [Ca²+]i. Am J Physiol Cell Physiol 2005; 288: 606–612.

Yang T. , Esteve E. , Pessah I.N. , Molinski T.F. , Allen P.D. , Lopez J.R. Elevated resting [Ca⁽²⁺⁾](i) in myotubes expressing malignant hyperthermia Ry R1 cDNAs is partially restored by modulation of passive calcium leak from the SR. Am J Physiol Cell Physiol 2007; 292: C1591–1598.

Fessenden J.D. , Feng W. , Pessah I.N. , Allen P.D. Mutational analysis of putative calcium binding motifs within the skeletal ryanodine receptor isoform, RyR1. J Biol Chem 2004; 279: 53028–53035.

Tong J. , Oyamada H. , Demaurex N. , Grinstein S. , McCarthy T.V. , MacLennan D.H. Caffeine and halothane sensitivity of intracellular Ca²⁺ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease. J Biol Chem 1997; 272: 26332–26339.

Treves S. , Larini F. , Menegazzi P. , Steinberg T.H. , Koval M. , Vilsen B. Alteration of intracellular Ca²⁺ transients in COS-7 cells transfected with the cDNA encoding skeletal-muscle ryanodine receptor carrying a mutation associated with malignant hyperthermia. Biochem J 1994; 301: 661–665.

Brini M. , Manni S. , Pierobon N. , Du G.G. , Sharma P. , MacLennan D.H. Ca²+ signaling in HEK-293 and skeletal muscle cells expressing recombinant ryanodine receptors harboring malignant hyperthermia and central core disease mutations. J Biol Chem 2005; 280: 15380–15389.

Wehner M. , Rueffert H. , Koenig F. , Neuhaus J. , Olthoff D. Increased sensitivity to 4-chloro-m-cresol and caffeine in primary myotubes from malignant hyperthermia susceptible individuals carrying the ryanodine receptor 1 Thr2206Met (C6617T) mutation. Clin Genet 2002; 62: 135–146.

Wehner M. , Rueffert H. , Koenig F. , Olthoff D. Functional characterization of malignant hyperthermia-associated RyR1 mutations in exon 44, using the human myotube model. Neuromuscul Disord 2004; 14: 429–437.